A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

Recent developments, however, suggest that strategies to treat pain are starting to match its complexity with a new sophistication. The management of chronic pain in general is now being broadly ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

Cupping therapy is an ancient practice that has gained popularity in recent years, particularly among athletes and individuals seeking alternative pain management solutions. This therapy involves ...

Revolutionary medical treatments offer new hope for chronic pain sufferers through advanced technology, targeted medications ...

People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...

Effective management of myofascial pain often involves various therapeutic techniques, including trigger point therapy, dry needling, and injections. Recent research has focused on evaluating the ...

If you’re in pain and you’re looking for relief in the form of an over-the-counter drug, you’ve got a slew of options.

Pain management is a chronic issue that plagues the Appalachian mountains – from pharmaceutical companies rolling out ...

The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

Elite sports stars, footballers and people living with chronic pain are just some of the clients of a Yorkshire myofascial release therapist. But what is myofascial release therapy? And why do they ...